Drugs / D2C7-IT
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06455605 | Mar 2025 → Jan 2029 expected | IDH-wildtype glioblastoma | Darell Bigner | Recruiting | No outcome recorded |
| Phase 1 | NCT04547777 | Jul 2021 → Jun 2027 expected | malignant glioma | Darell Bigner | Recruiting | No outcome recorded |
| Phase 1 | NCT04160494 | Feb 2020 → Jun 2024 overdue | malignant glioma | Darell Bigner | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02303678 | May 2015 → May 2019 | malignant glioma | Darell Bigner | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05734560 | Sep 2023 → Oct 2026 expected | glioblastoma | Darell Bigner | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D2C7-IT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05734560 ↗ |
| Known as | D2C7 Immunotoxin | “This is a Phase I study to determine the maximum tolerated dose (MTD) and/or recommended phase II dose of D2C7-IT (D2C7 Immunotoxin) when delivered intratumorally by...” NCT02303678 ↗ |
| Known as | D2C7-(scdsFv)-PE38KDEL | “To address this need, we have developed a novel tumor-targeted immunotoxin (IT), D2C7-(scdsFv)-PE38KDEL (D2C7-IT), by fusing the single chain variable fragment (scFv) from the...” PMID 28286803 ↗ 2016 |
| Known as | D2C7-immunotoxin (IT) | “D2C7-immunotoxin (IT), a dual-specific IT targeting wild-type epidermal growth factor receptor (EGFR) and mutant EGFR variant III (EGFRvIII) proteins, demonstrates encouraging...” PMID 36753564 ↗ Feb 20231“The purpose of this research study is to determine the safety and efficacy of administering a single intracerebral (within the brain) dose of investigational compounds called...” NCT05734560 ↗ |
| Action | Deplete | “In vitro cytotoxicity data showed that D2C7-IT can effectively inhibit protein synthesis and kill a variety of EGFRwt-, EGFRvIII-, and both EGFRwt- and EGFRvIII-expressing...” PMID 28286803 ↗ 2016 |
| Modality | Protein / enzyme biologic | “D2C7-(scdsFv)-PE38KDEL (D2C7-IT) is a novel recombinant Pseudomonas exotoxin A-based immunotoxin (IT)” PMID 28013405 ↗ Dec 2016 |
| Route | Other | “delivered intratumorally by convection-enhanced delivery (CED)” NCT02303678 ↗ |
| Target | EGFR | “targeting both wild-type epidermal growth factor receptor (EGFRwt) and mutant EGFR variant III (EGFRvIII) proteins overexpressed in glioblastomas” PMID 28013405 ↗ Dec 2016 |